Inovio Pharmaceuticals Inc (INO): DNA Vaccine INO-4500 Delivery-for-Lassa-...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	13
Posts	3218
Boards Moderated	0
Alias Born	04/26/2007

Lakers_w

Re: None

Friday, 11/27/2020 12:15:23 AM

Friday, November 27, 2020 12:15:23 AM

DNA Vaccine INO-4500 Delivery-for-Lassa-Virus P1 starts 12/7/20

Geneva researchers Dr. Connie Schmaljohn, Senior Research Scientist and Dr. Kathleen Cashman, Co- Investigator at the U.S. Army Medical Research Institute of Infectious Diseases, in collaboration with Dr. Kate Broderick, Senior Director of Research and Development at Inovio Pharmaceuticals, are developing a way to improve DNA vaccine delivery for Lassa fever through the use of an intradermal electroporation (ID-EP) device.

NCT04093076

Drug: INO-4500
Device: CELLECTRA™ 2000
Drug: Placebo

Sponsor/Collaborators:
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations (CEPI)
Number Enrolled: 220

Official Title:
Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4500 in Combination With Electroporation in Healthy Volunteers in Ghana
Estimated Study Start Date :
December 7, 2020
Estimated Primary Completion Date :
July 2022

https://genevausa.org/wp-content/uploads/2018/08/DNA-Vaccine-Delivery-for-Lassa-Virus.pdf

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
https://clinicaltrials.gov/ct2/show/NCT04093076?term=Inovio+and+Lassa&draw=2&rank=1